MEA Diabetic Neuropathy Market

MEA Diabetic Neuropathy Market Size (2023 to 2028)

The Middle East & Africa Diabetic neuropathy market was worth USD 0.25 billion in 2023 and is estimated to be growing at a CAGR of 7.45%, to reach USD 0.36 billion by 2028.

The growing patient population suffering from diabetes in the Middle East and Africa is one of the key factors propelling the growth of the MEA diabetic neuropathy market. Approximately 24 million adults in the African region have diabetes, with Type 2 diabetes being the most prevalent form of the disease. The high mortality rate associated with diabetes has prompted the MEA government to take several preventive measures. Lifestyle changes, consumption of sugary foods, high alcohol consumption, hormonal imbalances and genetic factors are among the leading causes of diabetes. Additionally, nearly 50 percent of diabetic patients suffer from diabetic neuropathy, further contributing to the market's growth. Overall, the rising prevalence of diabetes is a significant driver of growth in the MEA healthcare market.

The growing aging population across the Middle East and Africa further fuels the growth of the MEA diabetic neuropathy market. Changes in their immune system happen in people with growing age and make them more susceptible to diabetic neuropathy, a nerve disorder that damages nerves throughout the body, often affecting the legs and feet. Moreover, individuals with high blood sugar levels are more prone to diabetic neuropathy, which can result in several complications, including urinary tract issues, digestive system problems, heart issues and blood vessel disorders.

The growing number of advancements in new treatments and therapies accelerates the growth of the MEA diabetic neuropathy market. Researchers have been focusing on developing advanced biomarkers that can aid in the early detection and treatment of diabetic neuropathy. Additionally, regenerative medicine is being manufactured for the treatment of diabetic neuropathy, which is in high demand. Medical devices are also being developed for diabetic neuropathy treatment to reduce pain and swelling near nerve damage. The growing number of initiatives and investments by governmental organizations and private organizations, favorable reimbursement policies and an increasing number of product approvals.

Lack of awareness about diabetic neuropathy issues among diabetic patients majorly hampers the MEA diabetic neuropathy market growth. Additionally, the high cost of treatment is another factor that impedes the market growth. Strict government regulations, a need for more skilled professionals, and a lengthy product approval process are other factors that slow down the market growth during the forecast period.

This research report on the MEA diabetic neuropathy market has been segmented and sub-segmented into the following categories:

By Disorder:

• Peripheral Neuropathy
• Autonomic Neuropathy
• Proximal Neuropathy
• Focal Neuropathy

By Treatment:

• Drugs
  • Analgesic
    • Topical
      • Capsaicin
      • Others
    • Opioid:
      • Morphine
      • Others
    • NSAIDs
      • Ibuprofen
      • Naproxen
      • Others
  • Antidepressants:
    • TCAs
      • Amitriptyline
      • Imipramine
      • Others
    • SNRIs
      • Duloxetine
      • Others
    • SSRIs
      • Citalopram
      • Paroxetine
      • Others
  • Anticonvulsant Drugs
    • Gabapentin
    • Pregabalin
    • Topiramate
    • Others
    • Other Drugs
• Radiotherapy
  • Transcutaneous Electrical Nerve Stimulation (TENS)
  • Others
  • Physiotherapy

By Distribution Channel:

• Hospitals
• Clinics
• Retail Pharmacy
• Online Pharmacy

By Country:

• KSA
• UAE
• Israel
• rest of GCC countries
• South Africa
• Ethiopia
• Kenya
• Egypt
• Sudan
• rest of MEA

The Middle East and African market accounted for a relatively low share of the global diabetic neuropathy market in 2022. However, the regional market is anticipated to showcase steady growth during the forecast period. The growing awareness of diabetic neuropathy in the population of the Middle East and Africa population, an increasing number of campaigns by public and private organizations to educate the public on the symptoms, effects and available treatment options for diabetic neuropathy contribute to the regional market growth.

Egypt captured a considerable share of the MEA market during the forecast period owing to the growing number of clinical trial centers. Researchers have identified the link between diabetic neuropathy and end-stage renal diseases, leading to a growing demand for early-stage treatment options among the population.

Saudi Arabia has also seen an increase in the number of patients suffering from diabetic neuropathy, with nearly two-thirds of the diabetic population in the country affected. This presents a significant opportunity for growth in the market.

The United Arab Emirates (UAE) has shown promising growth potential in the market due to the increasing number of manufacturing facilities in the country. Additionally, the availability of diabetic neuropathy treatment in various hospitals and specialized clinics has created a growing demand for advanced treatment options.

KEY MARKET PLAYERS:

Johnson & Johnson (Janssen Global Services, LLC), Boehringer Ingelheim GmbH, NeuroMetrix, Inc., Eli Lilly and Company, GlaxoSmithKline plc, Lupin Limited, Pfizer Inc., Astellas Pharma Inc., Glenmark Pharmaceuticals Ltd., Arbor Pharmaceuticals, LLC and Depomed, Inc. are a few of the promising players in the MEA diabetic neuropathy market.